Article
Biochemistry & Molecular Biology
Hiroaki Iwamoto, Kouji Izumi, Ryunosuke Nakagawa, Ren Toriumi, Shuhei Aoyama, Taiki Kamijima, Takafumi Shimada, Hiroshi Kano, Tomoyuki Makino, Renato Naito, Suguru Kadomoto, Hiroshi Yaegashi, Shohei Kawaguchi, Takahiro Nohara, Kazuyoshi Shigehara, Yoshifumi Kadono, Atsushi Mizokami
Summary: This study investigated the efficacy of serum CCL2 as a prognostic biomarker for non-metastatic castration-sensitive prostate cancer (nmCSPC), and found that high CCL2 levels were associated with worse overall survival and cancer-free survival.
Review
Oncology
Catherine S. Johnson, Leah M. Cook
Summary: One of the challenges in improving survival of prostate cancer is designing new therapies to target bone metastases. Although regulation of the bone environment has been well characterized, current bone-targeted therapies have limited impact on patient survival, highlighting the complexity of the tumor-bone environment. Chemokine signaling is an important factor in promoting prostate cancer progression in the bone. Understanding and targeting this signaling pathway may provide promising options for treating bone metastasis.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Cinzia Baldessari, Stefania Pipitone, Eleonora Molinaro, Krisida Cerma, Martina Fanelli, Cecilia Nasso, Marco Oltrecolli, Marta Pirola, Elisa D'Agostino, Giuseppe Pugliese, Sara Cerri, Maria Giuseppa Vitale, Bruno Madeo, Massimo Dominici, Roberto Sabbatini
Summary: Bone metastases and bone health are important considerations in the management of prostate cancer patients. This review discusses the biology and clinical implications of bone metastases, as well as current therapeutic strategies. The importance of evaluating bone health and considering specific treatments is emphasized to address the risks associated with both poor bone health and bone metastasis.
Article
Biochemistry & Molecular Biology
Zilong Yao, Pengyu Chen, Liuyi Fan, Peisheng Chen, Xianrong Zhang, Bin Yu
Summary: The study demonstrates that moderate running can significantly improve trabecular bone in mice tibias by increasing the number of osteoblasts and activating signaling pathways such as CCL2, contributing to enhanced bone formation.
Article
Immunology
Gregory P. Takacs, Christian J. Kreiger, Defang Luo, Guimei Tian, Julia S. Garcia, Loic P. Deleyrolle, Duane A. Mitchell, Jeffrey K. Harrison
Summary: Glioblastoma (GBM) is a highly malignant brain tumor with poor survival rates. The tumor microenvironment (TME) of GBM is characterized by immunosuppressive cells, including CCR2(+)/CX3CR1(+) myeloid-derived suppressor cells (MDSCs). These MDSCs are recruited to the TME through the chemokines CCL2 and CCL7. Targeting CCL2 and CCL7 may be a promising strategy for GBM treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Ming Li, Caiping Ding, Dong Zhang, Weiwei Chen, Zejun Yan, Zikang Chen, Zhiyong Guo, Longhua Guo, Youju Huang
Summary: An effective method to diagnose castration-resistant prostate cancer bone metastasis (PCa-BM) using dye differentiated superposition enhancement colorimetric biosensors is developed. The method allows for naked-eye quantitative detection of alkaline phosphatase (ALP) with excellent accuracy. The technique can recognize and capture even slight variations in visual information by utilizing color-recombining enhancement effects.
Article
Oncology
Chuan-Yu Sun, Yuan-Yuan Mi, Sheng-Yang Ge, Qing-Feng Hu, Ke Xu, Yi-Jun Guo, Yi-Fan Tan, Yang Zhang, Fan Zhong, Guo-Wei Xia
Summary: This study explores the biological function of periostin (POSTN) in prostate cancer (PCa) bone metastasis. It is found that inhibiting POSTN can alleviate PCa bone metastasis and there is a positive feedback loop between PCa and osteoblasts mediated by POSTN. POSTN regulates PCa and osteoblast function through integrin receptors. These findings highlight the importance of targeting POSTN as a therapeutic approach for PCa bone metastasis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Adrien Guerard, Victor Laurent, Gaelle Fromont, David Esteve, Julia Gilhodes, Edith Bonnelye, Sophie Le Gonidec, Philippe Valet, Bernard Malavaud, Nicolas Reina, Camille Attane, Catherine Muller
Summary: Bone metastasis is a common and deadly complication of prostate cancer, and adipocyte-rich bone marrow cells may contribute to the migration of cancer cells through the release of chemokines. Factors such as obesity and aging can exacerbate the aggressiveness of tumors and may require evaluation of the CCR3/CCL7 axis for potential pharmacological interventions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Hongmei Li, Tingting Xu, Qingchu Hua, Li Wang, Yue Chen
Summary: Bone metastasis is common in prostate cancer patients, and Lu-177-DOTA-ibandronic acid (Lu-177-DOTA-IBA) is a promising therapeutic radiopharmaceutical for its treatment. We present a case of refractory bone pain due to bone metastasis, which showed an excellent response to 3 cycles of Lu-177-DOTA-IBA therapy. The patient did not experience any observable adverse reactions.
CLINICAL NUCLEAR MEDICINE
(2023)
Review
Immunology
Teizo Yoshimura, Chunning Li, Yuze Wang, Akihiro Matsukawa
Summary: Breast cancer is a common cancer worldwide, and metastasis is the main cause of cancer-related death. Human monocyte chemoattractant protein-1 (MCP-1/CCL2) was identified as a chemotactic factor for monocytes, and its role in cancer development and progression was investigated. Studies showed positive correlations between MCP-1 production in tumors and TAM infiltration, as well as cancer progression. MCP-1 was found to promote breast cancer metastasis to the lung and brain, but not bone. The mechanisms of MCP-1 production in the breast cancer microenvironment were also reported.
CELLULAR & MOLECULAR IMMUNOLOGY
(2023)
Article
Oncology
Shang Su, Jingchen Cao, Xiangqi Meng, Ruihua Liu, Alexandra Vander Ark, Erica Woodford, Reian Zhang, Isabelle Stiver, Xiaotun Zhang, Zachary B. Madaj, Megan J. Bowman, Yingying Wu, H. Eric Xu, Bin Chen, Haiquan Yu, Xiaohong Li
Summary: This study is the first to reveal the contribution of the bone microenvironment to enzalutamide resistance and identifies PTH1R as a feasible target to overcome resistance in prostate cancer bone metastases.
Article
Radiology, Nuclear Medicine & Medical Imaging
Ricarda Hinzpeter, Livia Baumann, Roman Guggenberger, Martin Huellner, Hatem Alkadhi, Bettina Baessler
Summary: This study successfully differentiated bone metastases not visible on CT but detected by (68) Ga-PSMA PET imaging using radiomics analysis, with a classification accuracy of 0.90, high sensitivity and specificity for bone metastases.
EUROPEAN RADIOLOGY
(2022)
Review
Medicine, General & Internal
Wietske I. Luining, Dennie Meijer, Max R. Dahele, Andre N. Vis, Daniela E. Oprea-Lager
Summary: Accurate staging and treatment strategy are crucial for prognosis in prostate cancer. Traditional imaging techniques like CT and bone scintigraphy have limitations in sensitivity and specificity compared to modern nuclear imaging methods using novel radiotracers with PET/CT technology, which outperform conventional imaging in detecting PCa.
Article
Pharmacology & Pharmacy
Thiago S. Lima, Luciano O. Souza, Diego Iglesias-Gato, Johanna Elversang, Flemming Steen Jorgensen, Tuula Kallunki, Martin A. Roder, Klaus Brasso, Jose M. A. Moreira
Summary: Itraconazole can re-sensitize docetaxel-resistant prostate and breast cancer cells by binding to ABC transporter protein ABCB1, inhibiting the transport of docetaxel.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Endocrinology & Metabolism
Carlotta Palumbo, Alberto Dalla Volta, Stefania Zamboni, Gherardo Mazziotti, Manuel Zamparini, Luca Triggiani, Paolo Borghetti, Filippo Maffezzoni, Roberto Bresciani, Luca Rinaudo, Francesca Valcamonico, Davide Farina, Stefano Maria Magrini, Alessandro Antonelli, Claudio Simeone, Alfredo Berruti
Summary: Degarelix administration is associated with a significant decrease in bone mineral density and increase in bone turnover markers. ALMI is a promising predictor of bone loss in prostate cancer patients receiving androgen deprivation therapy, and changes in ALMI during therapy are associated with bone turnover derangement favoring bone quality alterations.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)